- 专利标题： FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA
-
申请号： US17599729申请日： 2020-03-27
-
公开(公告)号： US20220054484A1公开(公告)日： 2022-02-24
- 发明人: Anjali Narayan AVADHANI , Anne Elizabeth O'HAGAN , Ademi Elena SANTIAGO-WALKER
- 申请人： Janssen Pharmaceutica NV
- 申请人地址： BE Beerse
- 专利权人： Janssen Pharmaceutica NV
- 当前专利权人： Janssen Pharmaceutica NV
- 当前专利权人地址： BE Beerse
- 优先权： EP19166428.3 20190329,EP19188971.6 20190730
- 国际申请： PCT/US2020/025166 WO 20200327
- 主分类号： A61K31/498
- IPC分类号： A61K31/498 ; A61P35/00
摘要：
Described here are methods of treating urothelial carcinoma in a patient comprising evaluating a biological sample from the patient for the presence of at least two fibroblast growth factor receptor (FGFR) genetic alterations and treating the patient with an FGFR inhibitor. Also described herein are methods of treating urothelial carcinoma in a patient harboring at least two fibroblast growth factor receptor (FGFR) genetic alterations comprising administering a FGFR inhibitor.
信息查询
IPC分类:
